Save 20% on PRs and Gain Exclusive Benefits with NNW Prime! Click to View Details

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP): IP Portfolio, Licensing and R&D are Keys to Growth in 2018

LXRP has global patents or patents-pending in more than 40 countries, including the U.S., Australia, China, the European Union and Canada Company is working through a C$250,000 budget for an 18-month collaborative research agreement with the National Research Council Licensing is a revenue generator, with LXRP offering to license its disruptive DehydraTECH™ technology in countries … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP): IP Portfolio, Licensing and R&D are Keys to Growth in 2018”

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Utilizes Oral Digestion Technology to Expand Product Line

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) recently announced its entry into a licensing agreement with Cannfections Group Inc. The agreement offers Lexaria the ability to provide commercial clients with high quality chocolate edibles using its proprietary DehydraTECH™ oral digestion technology. An article discussing the company reads: “Lexaria has developed various products for demonstration, testing and … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Utilizes Oral Digestion Technology to Expand Product Line”

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expanding Best-in-Class Product Line

Lexaria has developed an oral digestion technology that may translate into lower dosages and shorter treatment regimens Company is expanding its edible product offerings through a licensing agreement with a Canadian cannabis chocolate manufacturer Lexaria continues to develop products for demonstration, testing and sales Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed DehydraTECH™, an … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expanding Best-in-Class Product Line”

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement to Create Cannabis-infused Edibles Utilizing DehydraTECH™ Delivery Technology

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) recently entered an agreement with a cannabis-infused edibles manufacturer, Cannfections Group Inc. The agreement is expected to generate new cannabis-based edible products using Lexaria’s patented DehydraTECH™ delivery technology. An article discussing the agreement reads: “On January 25, 2018, Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced that it had … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement to Create Cannabis-infused Edibles Utilizing DehydraTECH™ Delivery Technology”

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement with Cannabis-Infused Edibles Manufacturer

Lexaria enters agreement with Cannfections to develop an innovative range of cannabis-infused chocolates and gummies incorporating its proprietary technology, DehydraTECH™ Cannfection’s formulation and manufacturing expertise can be offered to other Lexaria licensee partners The agreement is expected to generate new cannabis-based edible products for domestic and international markets On January 25, 2018, Lexaria Bioscience Corp. … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement with Cannabis-Infused Edibles Manufacturer”

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Potential to Lower Medication Doses Using Advanced Drug Delivery

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) has developed DehydraTECH™, a drug delivery platform that can be applied to various ingestible products such as foods, beverages, oral suspensions, tablets, capsules and more. An article discussing the company’s innovative drug delivery technology reads: “Lexaria’s DehydraTECH™ oral digestion technology is a ‘back office’ process that allows non-psychoactive cannabinoids, … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Potential to Lower Medication Doses Using Advanced Drug Delivery”

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Offers Potentially Safer Method of Delivering Drug Therapies

Only company in the world with patent for the oral or ingestible delivery of all non-psychoactive cannabinoids Uplisted to OTCQX® Best Market Licensing model generates profit margins in excess of 90 percent A new report by the National Academies of Sciences, Engineering and Medicine is the most comprehensive analysis of existing research on e-cigarettes, according … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Offers Potentially Safer Method of Delivering Drug Therapies”

NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Platform Expands Portfolio

Food bioscience company Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) strategic focus for 2018 is on out-licensing its proprietary technology, DehydraTECH™. The company intends to out-license to third-party partners using a high margin royalty model. An article discussing the company’s drug delivery platform reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Platform Expands Portfolio”

Disrupting Drug Delivery Platform Keeps Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Portfolio Growing

Patented technology promotes healthier administration of active pharmaceutical ingredients, including cannabidiol (CBD), psychoactive cannabinoids (THC), nicotine, fat soluble vitamins and nonsteroidal anti-inflammatory drugs Active pharmaceutical ingredient market expected to exceed $239 billion by 2025 19 patent applications filed in U.S. and internationally encompassing 44 countries Lab tests in 2018 include topical CBD skin cream, nicotine … Continue reading “Disrupting Drug Delivery Platform Keeps Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Portfolio Growing”

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Eyes Bright Future Following 2017 Success

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) demonstrated several transformative developments in 2017. The company’s Intellectual Property (“IP”) was strengthened, it was awarded broad patents, and it secured finances during the year. Now, Lexaria is concentrating on making 2018 an even more fruitful year. An article discussing the company’s recent progress reads: “The company’s stock has … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Eyes Bright Future Following 2017 Success”

Contact us: 212.418.1217